Pancreazim 10000 gastro-resistant tablets 50 pcs

• active substance: pancreatin;
• 1 gastroresistant tablet contains pancreatin with an enzymatic activity of at least 10,000 lipolytic units of Ph. Eur., 7,500 amylolytic units Ph. Eur., 400 proteolytic units Ph. Eur.;
• auxiliary substances: sodium chloride, colloidal anhydrous silicon dioxide, microcrystalline cellulose, crospovidone, croscarmellose sodium, povidone 25, magnesium stearate, methacrylate copolymer dispersion, talc, propylene glycol, titanium dioxide (E 171), carmoisin (E 122).

Increased sensitivity to the active substance and other components of the medicinal product. Acute pancreatitis, exacerbation of chronic pancreatitis, intestinal obstruction.

From the side of the cardiovascular system: the frequency is unknown: tachycardia.

From the side of the immune system: very rarely: allergic reactions of the immediate type (skin rash, itching, sneezing, lacrimation, bronchospasm), anaphylactic reactions. The frequency is unknown: carmoisin dye (E 122) can cause allergic reactions.

From the gastrointestinal tract: very rarely: when using high doses of pancreatin (more than 10,000 units of Ph. Eur. lipase / kg of body weight / day), constrictions may form in the ileocecal area and in the ascending part of the colon; diarrhea, abdominal pain, nausea, vomiting, change in the nature of stools; possible development of intestinal obstruction, constipation.

From the side of the skin and subcutaneous tissues: the frequency is unknown: urticaria, hyperemia, itching, angioedema.

From the genitourinary system: the frequency is unknown: increased excretion of uric acid with urine is possible, especially when using high doses of pancreatin. To avoid the formation of uric acid stones in such patients, the content of uric acid in the urine should be monitored.

General disorders: frequency unknown: feeling of heat, general weakness.

The dose of the drug depends on the deficiency of pancreatic enzymes in the duodenum and is set individually.

If there are no other recommendations, as well as in case of consumption of difficult-to-digest vegetable food, fatty or unusual food, take 1-2 tablets. In other cases mentioned above, when digestive disorders occur, the recommended dose is 2–4 tablets. If necessary, the dose of the drug can be increased. Increasing the dose in order to reduce symptoms of the disease, such as steatorrhea or abdominal pain, should be carried out only under the supervision of a doctor. The daily dose of lipase should not exceed 15,000 – 20,000 IU Ph. Eur. per 1 kg of body weight.

Tablets should be taken during meals, swallowing whole and with a large amount of liquid, for example, 1 glass of water.

The duration of treatment depends on the course of the disease and is determined by the doctor individually.

Use during pregnancy or breastfeeding

During pregnancy or breastfeeding, the use of the drug should be avoided.

Children

There is no experience of using the drug in children, so it is not recommended to prescribe it to this age category of patients.

The ability to influence the speed of reaction when driving vehicles or other mechanisms

No influence on the ability to drive a car and other mechanical means was observed.

Symptoms Side effects may increase. Hyperuricemia and hyperuricosuria have been observed when taking extremely high doses of other pancreatic powder preparations.

Treatment. Drug discontinuation, adequate hydration, and symptomatic therapy.

When using pancreatin, a decrease in iron absorption is possible, therefore, if necessary, additional iron preparations should be prescribed.

Simultaneous use of antacids that contain calcium carbonate and/or magnesium hydroxide can reduce the effectiveness of pancreatin.

Simultaneous use with tannin, alcohol-containing products can lead to a decrease in the effectiveness of pancreatin.

With simultaneous use of bicarbonates and cimetidine with large doses of pancreatic enzymes, it is recommended to periodically analyze the concentration of folic acid salts in the blood serum and provide additional folic acid intake, if necessary.

Folic acid. Absorption of folic acid may be reduced in patients taking pancreatic enzyme preparations, so monitoring of folic acid levels is recommended during concomitant use.

Acarbose, miglitol. It is possible that pancreatic enzyme preparations may reduce the effect of these antidiabetic agents. Therefore, during concomitant use with pancreatin, it is recommended to monitor the effect of antidiabetic agents on the patient’s blood sugar level.

Store in the original packaging at a temperature not higher than 25 ºС.

Keep out of the reach of children.